ADVENZYMESNSEAdvanced Enzyme Technologies LimitedMediumNeutral
Announced Sat, 9 May · 14:13 IST

Advanced Enzyme Technologies Limited has informed the Exchange regarding Appointment of Mr. Pradip Bhailal Shah as Independent Director of the company w.e.f. Jun 12, 2026.

Management Changes View source PDF

ADVENZYMES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+2.8%1-day move
₹361.75
prior close
₹378.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+7.4+6.0+6.9+6.6+2.8+1.2+0.8+0.1-0.1+7.7+7.5+0.2-8.7
Up moveDown movePending
AI summary

Advanced Enzyme Technologies reported strong FY26 consolidated results with revenue of Rs 7,458 million (up 17% YoY) and net profit of Rs 1,736 million (up 30% YoY). The Board recommended a final dividend of Rs 1.35 per share (67.5% payout) while deferring any interim dividend to preserve capital for strategic opportunities. Mr. Pradip Bhailal Shah was appointed as Additional Independent Director effective June 12, 2026 for a 5-year term, subject to shareholder approval. Additionally, Mr. Mukund Kabra was re-appointed as Whole-time Director for another 5 years from April 2027. The company also allotted 49,350 equity shares under its ESOP scheme 2022 and reappointed M S K A & Associates as statutory auditors for a second 5-year term.

Likely market impact

The strong financial performance and dividend recommendation are positive signals for shareholders. The appointment of an independent director strengthens board governance. The decision to preserve capital for strategic purposes suggests the company may pursue acquisitions or corporate actions.